Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
Key Points
Key Points
- Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
- NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.
Treatment
...reatment
...therapy: For Patients with Stage II to IVA...
...ion 1.1For all nasopharyngeal carcinoma...
...mendation 1.2For all NPC patients, both sequential...
...mmendation 1.3For all NPC patients, a pre...
...commendation 1.4For all NPC patients, gross tu...
...commendation 1.5For NPC patients who have und...
...1.6The delineation of elective nodal vol...
...erapy Sequence...
...ation 2.1For T2N0 (AJCC 8th) NPC patient...
...2.2For T1-2N1 (AJCC 8th) NPC patients,...
...mmendation 2.3For Stage III–IVA (ex...
...2.4For Stage III–IVA (except T3N0) (AJ...
...ation 2.5For T3N0 (AJCC 8th) NPC patients,...
...ncurrent Chemother...
...ommendation 3.1For all NPC patients wit...
...ecommendation 3.2For all NPC patients wi...
...on 3.3For NPC patients with a contraindica...
...commendation 3.4For NPC patients with a cont...
...nduction Chemot...
...mendation 4.1For all NPC patients receiving induc...
...tion 4.2For NPC patients receiving...
...commendation 4.3For NPC patients recei...
...t Chemotherapy...
...dation 5.1For all NPC patients receiving ad...
...ation 5.2For all NPC patients receiving adjuv...
...ommendation 5.3For all NPC patients receiving adj...
...gure 1. Stage II to IVA Nasopharyng...